Aegerion Pharmaceuticals, Inc. Presents Data From Phase 3 Extension Study Of JUXTAPID™ (Lomitapide) Capsules In Homozygous Familial Hypercholesterolemia (Hofh) At American Heart Association Scientific Sessions

Published: Nov 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, today presented data from its open-label Phase 3 extension study of JUXTAPID™ (lomitapide) capsules in patients with homozygous familial hypercholesterolemia (HoFH). The data were presented in a poster at the American Heart Association's Scientific Sessions taking place in Dallas.

Help employers find you! Check out all the jobs and post your resume.

Back to news